LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more
LungLife AI Inc (LLAI) - Net Assets
Latest net assets as of June 2024: GBX7.93 Million GBX
Based on the latest financial reports, LungLife AI Inc (LLAI) has net assets worth GBX7.93 Million GBX as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX9.06 Million) and total liabilities (GBX1.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX7.93 Million |
| % of Total Assets | 87.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 19.13 |
LungLife AI Inc - Net Assets Trend (2018–2023)
This chart illustrates how LungLife AI Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LungLife AI Inc (2018–2023)
The table below shows the annual net assets of LungLife AI Inc from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | GBX7.91 Million | -39.78% |
| 2022-12-31 | GBX13.14 Million | -34.72% |
| 2021-12-31 | GBX20.13 Million | +3.09% |
| 2020-12-31 | GBX19.53 Million | +387.25% |
| 2019-12-31 | GBX-6.80 Million | -119.27% |
| 2018-12-31 | GBX-3.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LungLife AI Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2923000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX3.00K | 0.04% |
| Other Comprehensive Income | GBX1.76 Million | 22.24% |
| Other Components | GBX91.27 Million | 1153.37% |
| Total Equity | GBX7.91 Million | 100.00% |
LungLife AI Inc Competitors by Market Cap
The table below lists competitors of LungLife AI Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bull Trading And Investment Ltd
TA:BULL
|
$158.54 |
|
LifeSafe Holdings PLC
LSE:LIFS
|
$158.65 |
|
Cue Health Inc.
NASDAQ:HLTHQ
|
$159.00 |
|
G2M Cap Corp.
V:GTM-P
|
$159.30 |
|
EMBRY HOLDINGS
BE:E3S
|
$158.16 |
|
MRC Allied Inc
PSE:MRC
|
$158.11 |
|
Marwyn Value Investors Limited
LSE:MVI
|
$157.51 |
|
Synthesis Energy Systems Inc
PINK:SYNE
|
$157.00 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LungLife AI Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 13,140,000 to 7,913,000, a change of -5,227,000 (-39.8%).
- Net loss of 5,413,000 reduced equity.
- Other comprehensive income increased equity by 186,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-5.41 Million | -68.41% |
| Other Comprehensive Income | GBX186.00K | +2.35% |
| Total Change | GBX- | -39.78% |
Book Value vs Market Value Analysis
This analysis compares LungLife AI Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | GBX-0.12 | GBX4.15 | x |
| 2019-12-31 | GBX-0.27 | GBX4.15 | x |
| 2020-12-31 | GBX0.77 | GBX4.15 | x |
| 2021-12-31 | GBX1.27 | GBX4.15 | x |
| 2022-12-31 | GBX0.52 | GBX4.15 | x |
| 2023-12-31 | GBX0.31 | GBX4.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LungLife AI Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11767.39%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.20x
- Recent ROE (-68.41%) is below the historical average (-32.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -330.92% | 1.36x | 0.00x | GBX-2.94 Million |
| 2019 | 0.00% | -3469.89% | 0.08x | 0.00x | GBX-4.06 Million |
| 2020 | -28.76% | -2737.21% | 0.01x | 1.10x | GBX-7.57 Million |
| 2021 | -36.98% | -3806.48% | 0.01x | 1.09x | GBX-9.46 Million |
| 2022 | -57.88% | -31691.67% | 0.00x | 1.14x | GBX-8.92 Million |
| 2023 | -68.41% | -11767.39% | 0.00x | 1.20x | GBX-6.20 Million |
Industry Comparison
This section compares LungLife AI Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $16,407,333
- Average return on equity (ROE) among peers: -40.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LungLife AI Inc (LLAI) | GBX7.93 Million | 0.00% | 0.14x | $158.54 |
| Abingdon Health Plc (ABDX) | $5.30 Million | -64.43% | 0.76x | $1.83K |
| CelLBxHealth plc (CLBX) | $40.33 Million | -37.22% | 0.17x | $941.82 |
| genedrive plc (GDR) | $3.59 Million | -19.24% | 0.36x | $1.10K |